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Reduced nitric oxide synthase activity in rats with chronic renal from clinical studies are limited, and the animal work,
disease due to glomerulonephritis. while informative, has been largely focused on the CRD
Background. Animal studies with systemic nitric oxide syn- model produced by reduction of functional renal massthase (NOS) inhibition and renal ablation, suggest that NO
[4–6]. We therefore sought to investigate a different modeldeficiency is both a cause and a consequence of chronic renal
of primary renal disease, leading to CRD. Since approxi-disease (CRD).
Methods. This study examined a glomerulonephritis (GN) mately 15% of the CRD in humans result from immune-
model of CRD to determine if NO is deficient. In addition to mediated renal disease [8], we chose an anti-glomerular
measuring indices of renal function (proteinuria, creatinine basement membrane glomerulonephritis (anti-GBM GN)clearance, structural damage), indices of total and renal nitric
model for study. In this rat experimentally induced anti-oxide production also were assessed (total NOX excretion, renal
GBM GN can result in CRD with glomerulosclerosisNOS activity, renal NOS protein abundance, plasma levels of
NOS substrate and endogenous inhibitor). after the acute inflammatory response has abated [9].
Results. Rats developed increasing proteinuria 12 to 20 weeks In the present study the two specific questions were
after induction of GN (with anti-glomerular basement mem- (1) does systemic and/or renal NO deficiency develop inbrane, GBM, antibody) and at 20 weeks exhibited reduced cre-
a GN model of CRD, and (2) if so, what mechanismsatinine clearances and increased glomerulosclerosis relative to
are involved? Rats were maintained for 20 weeks afterage-matched controls. Total NOX excretion was reduced and
the renal cortical NOS activity and neuronal NOS (nNOS) administration of anti-rat GBM antibody and then com-
abundance was decreased relative to controls. There was no pared to time controls. Periodic 24-hour urines were
impact on renal or aortic endothelial NOS expression or cere- collected to monitor proteinuria and total NO produc-bellar nNOS. The plasma l-arginine (Arg) concentration was well
tion (from the stable NO oxidation products, NO2 maintained but plasma asymmetric dimethylarginine (ADMA)
NO3  NOX). Afterwards, the rats were sacrificed andconcentration increased in GN versus control animals.
Conclusions. Total and renal NOS activity is reduced in the tissues harvested for measurement of NOS protein abun-
GN model of CRD due to increased circulating endogenous dance and NOS activity as well as for histologic assess-
NOS inhibitors and decreased renal nNOS abundance. ment of injury. A blood sample was obtained for determi-
nation of levels of creatinine, BUN, arginine (Arg) and
the endogenous NOS inhibitor asymmetric dimethyl-
There is clinical and experimental evidence that chronic arginine (ADMA).
progressive renal disease (CRD) and end-stage renal dis-
ease (ESRD) is associated with nitric oxide (NO) defi-
METHODSciency [1–6]. In addition, experimentally-induced NO de-
ficiency causes CRD [7]. These associations suggest a Male Sprague-Dawley rats (N  14) were maintained
possible vicious cycle that could contribute to progres- on a nutritionally complete, low NOX diet (ICN AIN 76C;
sion of renal disease. The mechanistic insights possible ICN Biomedicals, Cleveland, OH, USA) and tap water ad
libitum. After baseline measurements in metabolic cages,
experimental rats (N  6) were pre-immunized (1 mgKey words: neuronal NOS, endothelial NOS, arginine, asymetric di-
sheep IgG in 1 mL Freund’s adjuvant, 6 sites intraderm-methylarginine, nitrate nitrite, ESRD, nitric oxide, progressive renal
disease. ally), and five days later received sheep anti-rat anti-GBM
antibody (1.5 to 3.0 mL/kg) by tail vein. Twenty-fourReceived for publication November 19, 2001
hour urine was collected in metabolic cages periodicallyand in revised form February 15, 2002
Accepted for publication March 8, 2002 and assayed for total urinary protein (Bradford assay)
and NOx by the Greiss reaction. After 20 weeks, GN 2002 by the International Society of Nephrology
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Fig. 2. The total number of damaged (sclerotic) glomeruli in control
() and GN ( ) rats are given in the first columns. Next the severityFig. 1. Twenty-four hour urinary protein excretion (UpV) versus time
of glomerular injury is given, with 1 representing mild damage, up toin rats with glomerulonephritis (GN, ) and controls (). *P  0.05,
25% of glomerulus involved;2 representing moderate damage with 26control vs. GN; whiskers denote difference vs. baseline value.
to 50% injury; 3 and4 representing severe damage of 51 to 75% and
76% or more global sclerosis, respectively. *P  0.05 control vs. GN.
rats and age-matched controls (N  8) were sacrificed.
Kidneys were prepared for histologic evaluation of glo-
(Fig. 2). Representative photomicrographs of the renalmerular injury (in a blinded fashion), NOS-activity mea-
histology are shown in Figure 3. In addition, BUN andsurement (determined by the conversion of [3H]-l-Arg to
plasma creatinine was elevated and 24-hour creatinine[3H]-l-citrulline) was measured in the soluble fraction of
clearance was reduced versus controls, reflecting approx-kidney cortex and medulla and expressed as the NG-mono-
imately 65% loss of renal function in GN rats (Table 1).methyl-l-arginine (L-NMMA; 10 mmol/L) and N-nitro-l-
As shown in Figure 4, the UNOXV was similar at base-arginine methyl ester (L-NAME; 20 mmol/L) inhibitable
line and higher at weeks 1 and 4 in GN versus controls,conversion (85% of total). Western blot analysis was
coincident with the acute inflammatory response to anti-conducted on kidney cortex [for endothelial (eNOS) and
GBM antibody. By week 8, UNOXV in the GN group hadneuronal NOS (nNOS); 200 g total protein), aorta (for
normalized to control values and at 20 weeks was signifi-eNOS; 100 g total protein) and cerebellum (for nNOS;
cantly reduced versus controls. Although plasma NOX10 g total protein). NOS protein abundance was ex-
concentration was higher in GN rats at 20 weeks versuspressed as integrated optical density, IOD of nNOS or
controls (Table 1), the ratio of plasma NOX to plasmaeNOS factored for Ponceau red stain (total protein
creatinine (to factor out the hemoconcentration of NOXloaded). Terminal blood was collected and assayed for
secondary to reduced renal clearance) was not differentNOX, creatinine (Cr), blood urea nitrogen (BUN), ADMA
between GN and controls. Together, the UNOXV and PNOXand Arg. Details of these various methods have been
data suggest that total NO production is reduced in thegiven previously [1, 3, 7, 10, 11].
GN rats with CRD versus controls.Statistical analysis was by one- and two-way ANOVA,
The plasma L-Arg concentrations were similar betweenunpaired t test and linear regression; P 0.05 was consid-
GN and controls whereas plasma ADMA was elevatedered statistically significant.
by approximately 3.5 (Table 1). Of note, the plasma
ADMA to Arg ratio was significantly elevated in GN ver-
RESULTS sus controls. When PADMA was factored for plasma creati-
nine, the difference between groups was less (0.044 The 24-hour urine protein excretion (UpV) rose10
0.005 vs. 0.030  0.003, GN vs. control, P  0.02), sug-on the day after anti-GBM antibody administration (Fig. 1).
gesting that most of the increase in PADMA was the resultUpV then fell to a stable but elevated value over the
of loss of renal clearance.next 12 weeks and then began to increase again in the
As shown in Figure 5, the NOS activity in the solubleGN rats. In contrast, controls showed only mild age-
fraction of renal cortex was reduced in the GN rats versusdependent increases in UpV over the 20 week observa-
controls. The abundance of the nNOS was also lower intion. The heavy proteinuria at 20 weeks in GN rats corre-
homogenates of renal cortex from GN (N 5) versus con-lated with significant glomerular sclerosis as well as an
increase in the severity of injury versus time controls trols. The nNOS protein abundance in cerebellum was
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Fig. 3. (A) Section from a control rat with 3 normal glomeruli. (B) A section from a GN rat also contains 3 glomeruli. The middle glomerulus
has 50% sclerosis (arrow), while that on the right shows mesangial expansion and matrix accumulation. The glomerulus on the left also shows
some increase mesangial matrix accumulation. Original magnification, 300.
Table 1. Blood and urine chemistry in rats after 20 weeks of CRD secondary to glomerulonephritis (post-GN)
or in controls aged over a similar period
Pcr BUN PARG PADMACCr PNOX
mg % mL/min/kg BW lmol/L PNOX/PCr lmol/L PADMA/PARG
Control 0.410.02 211 6.30.3 182 0.510.06 1018 1.080.11 0.0110.001
Post-GN 0.980.20 3810 2.40.3 274 0.350.07 11713 3.810.95 0.0340.008
P value 0.025 0.05 0.001 0.02 NS NS 0.035 0.035
nates of aorta (100 g protein) between GN rats and
controls (2.33  0.17 and 2.63  0.33 IOD units, respec-
tively). Although there was inadequate protein available
to perform Western blots on medulla, the NOS activity
was markedly reduced in GN versus controls (0.80 0.16
vs. 1.41  0.17 pmol cit/min/mg protein, P  0.02).
DISCUSSION
The main novel finding in the present study is that in
a rat model of chronic progressive renal disease second-
ary to GN, there are reductions in both total and renal
NO generation. These findings agree with several reports
in the 5/6th ablation or ablation/infarction models of CRD
in the rat [4–6] and support the hypothesis that irre-
spective of etiology, CRD is a state of NO deficiencyFig. 4. Total nitric oxide (NO) production, indicated by 24-hour uri-
nary NOX excretion (UNOXV) in control () and GN () rats. *P  [1–6, 12].
0.05, control vs. GN. Whiskers denote difference vs. baseline value. To our knowledge, this study represents the first long-
term evaluation of the NO system in experimentally-
induced, immune-mediated renal disease. It is well known
that early in GN, during the acute inflammatory response,similar in controls and rats with GN (data not shown).
increased renal NO production [from stimulated induc-In contrast to the nNOS, the eNOS abundance in renal
ible NOS (iNOS)] occurs that contributes to the earlycortex was not altered in the CRD rats (data not shown).
We also observed a similar eNOS abundance in homoge- pathology [13–15]. Indeed, since the severity of the acute
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the plasma levels of creatinine and ADMA in the present
study, suggesting that reduced renal clearance contrib-
utes to the elevated ADMA. Increased ADMA levels
also can occur in humans with active renal disease [1],
but in contrast to the ESRD patients not all CRD patients
have elevated plasma ADMA despite a similar loss of
renal clearance [11]. We have suggested that some individ-
uals might be able to mobilize the enzyme dimethylargin-
ine dimethylaminohydrolase (DDAH), which degrades
ADMA, thus for a limited time maintaining a normal
PADMA despite increased PCr.
We also have reported that the increased PADMA in
renal failure patients is associated with functional impair-
ment of endothelial NO generation. When plasma from
ESRD patients (with PADMA levels similar to those in the
GN rat) was incubated with cultured vascular endothelial
cells, a marked inhibition of eNOS activity occurred [18].
In the CRD patients, plasma from those with elevated
PADMA always inhibited eNOS activity in cultured endo-
thelial cells while those with normal PADMA had no inhibi-
tory effect [11]. Furthermore, inhibition of eNOS activity
in vitro was seen when endothelial cells were incubated
with artificial solutions containing a similar amount of
ADMA as found in the GN rat plasma [11, 18]. There-
fore, the increased PADMA/PArg seen in GN rats probably
contributed to the reduction in total NO generation
Fig. 5. (A) Renal cortical nitric oxide synthase (NOS) activity in control (from 24-hour UNOXV).and GN rat. (B) Relative abundance of the neuronal NOS isoform
We expect that the increased PADMA/PArg in GN rats(nNOS; factored for total protein loaded, from Ponceau red stain) in
control and GN rats. *P  0.05. also contributed to a reduced renal NOS activity. In
addition, when measured in vitro after removal of endog-
enous ADMA and Arg, NOS activity remained signifi-
cantly reduced in both cortex and medulla of kidneys
inflammatory response is directly related to later devel- from GN rats. The decline in renal cortical NOS activity
opment of CRD due to GN [9], the early increase in NO is associated with a decline in renal cortical nNOS abun-
can be considered to contribute to the level of chronic dance. Since nNOS resides in the cytosol, and the in
injury. This iNOS induction and increased NO genera- vitro NOS activity assay was conducted on the soluble
tion is relatively short lived [15], and as shown here, by fraction, it is likely that decreased renal nNOS abun-
eight weeks after immunization total NO generation has dance contributes to the reduced renal NOS activity in
returned to normal, while by 20 weeks the total NO rats with CRD secondary to GN. Of course, we recognize
production is reduced. The reduction in total somatic NO that many factors other than protein abundance will con-
generation was substantial (24-hour UNOXV was 60% tribute to the intrinsic activity of the NOS, and may also
control) and since renal generation of NO contributes be altered in GN.
only a few % to the total [16], it is likely that NO genera- This study identifies two separate mechanisms by
tion also is reduced from non-renal sites in this GN model which renal NO production is reduced in the rat with
of CRD. CRD secondary to GN. Reductions in renal NOS activity
Total somatic NO production could be reduced via an and nNOS abundance also have been reported pre-
increase in the level of endogenous inhibitors. An in- viously for the renal ablation models of CRD, although
crease in the ratio of concentrations of ADMA (an Arg as yet there is no mechanistic explanation [4–6]. In the
analog that functions as an endogenous NOS inhibitor) present study nNOS protein expression in cerebellum of
to Arg (native NOS substrate), as occurred in the GN GN rats is normal, suggesting that the nNOS down-
rats, will reduce NO generation throughout the body. regulation is not ubiquitous, although reduced nNOS
In humans with ESRD, plasma ADMA levels increase expression in other non-renal tissue cannot be ruled out.
substantially [2, 3, 17], and according to Vallance and In this GN model of CRD there was preservation of
colleagues this is due to reduced renal clearance of the the eNOS protein abundance in kidney cortex, as well
as in aorta, with only the renal nNOS abundance beingmethylated Arg [17]. There is a good correlation between
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2. Schmidt RJ, Yokota S, Tracy TS: Nitric oxide production is lowreduced. This contrasts with the more severe injury seen
in end stage renal disease patients on peritoneal dialysis. Am J Phys-in the advanced 5/6th ablation model where decreases in iol (Renal Physiol) 276:F794–F797, 1999
both renal and aortic eNOS abundance were reported [5]. 3. Schmidt R, Domico J, Samsell L, et al: Indices of activity of the
nitric oxide system in patients on hemodialysis. Am J Kidney DisHowever, early (2 to 3 weeks) after 5/6th renal ablation/
34:228–234, 1999infarction we found that the nNOS, but not eNOS pro- 4. Vaziri ND, Ni Z, Wang XQ, et al: Downregulation of nitric oxide
tein is reduced (abstract; Wagner et al, J Am Soc Nephrol synthase in chronic renal insufficiency: Role of excess PTH. Am
J Physiol (Renal Physiol) 274:F642–F649, 199812:828A, 2001), suggesting that the renal nNOS is most
5. Aiello S, Noris M, Todeschini M, et al: Renal and systemic nitricsensitive to developing renal damage. There are few
oxide synthesis in rats with renal mass reduction. Kidney Int 52:171–
clinical data on NOS protein abundance in renal disease. 181, 1997
6. Roczniak A, Fryer JN, Levine DZ, Burns KD: DownregulationBy immunohistochemistry, the glomerular expression of
of neuronal nitric oxide synthase in the rat remnant kidney. J AmeNOS is reduced in patients with Wegener’s granuloma-
Soc Nephrol 10:704–713, 1999tosis [19] and also in GN, when there is severe renal 7. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide
injury [20]. To date there has been no assessment of the synthesis in the rat produces systemic hypertension and glomerular
damage. J Clin Invest 90:278–281, 1992renal nNOS.
8. United States Renal Data System: USRDS 1990 Annual DataWe do not yet understand the intermediate mecha-
Report. Bethesda, The National Institutes of Health, National In-
nisms that link developing CRD with falls in renal nNOS stitute of Diabetes and Digestive and Kidney Diseases, 1990, pp
D.2–D.25abundance. However, the functional implications are sig-
9. Scandrett AL, Kissane J, Lefkowith JB: Acute inflammationnificant. The renal nNOS is most abundant in macula
is the harbinger of glomerulosclerosis in anti-glomerular base-densa and plays an important “permissive” vasodilatory ment membrane nephritis. Am J Physiol (Renal Physiol) 268:F258–
role in the tubuloglomerular feedback regulation of GFR F265, 1995
10. Xiao S, Erdely A, Wagner L, Baylis C: Uremic levels of BUN[21]. Thus, a decline in renal cortical nNOS will cause
do not cause nitric oxide deficiency in rats with normal renalrenal vasoconstriction and falls in GFR, and this un-
function. Am J Physiol (Renal Physiol) 49:F996–F1000, 2001
doubtedly contributes to the overall fall in renal function 11. Xiao S, Wagner L, Schmidt RJ, Baylis C: Circulating eNOS
inhibitory factor in some patients with chronic renal disease. Kid-seen in the GN rats. Loss of the “antigrowth, antifibrotic”
ney Int 59:1466–1472, 2001influence of NO, irrespective of its source of origin, also
12. Klahr S: The role of nitric oxide in hypertension and renal diseasewill promote the development of structural injury. progression. Nephrol Dial Transplant 16(Suppl 1):60–62, 2001
In conclusion, CRD secondary to GN leads to soma- 13. Jansen A, Cook T, Taylor GM, et al: Induction of nitric oxide
synthase in rat immune complex glomerulonephritis. Kidney Inttic and renal NO deficiency. The increased circulating
45:1215–1219, 1994ADMA (secondary to loss of renal clearance) is a likely
14. Narita I, Border WA, Ketteler M, Noble NA: Nitric oxide
contributor to the decreased somatic NO production. mediates immunologic injury to kidney mesangium in experimental
High PADMA will inhibit renal NO production and the glomerulonephritis. Lab Invest 72:17–24, 1995
15. Lianos EA, Liu J: Changes in inducible nitric oxide synthaselocal decrease in nNOS abundance will exacerbate local
expression in experimental glomerulonephritis. Proc Soc Exp Biolrenal NO deficiency, which is likely to contribute to the Med 215:405–411, 1997
progression of renal disease as well as causing functional 16. Baylis C, Vallance P: Editorial Review: Measurement of nitrite
and nitrate (NOx) levels in plasma and urine; what does this mea-declines. This rat model of CRD is less aggressive than
sure tell us about the activity of the endogenous nitric oxide. Currthe ablation/infarction models usually studied and pro-
Opin Nephrol Hypertens 7:1–4, 1998
vides an animal model that is more representative of 17. Vallance P, Leone A, Calver A, et al: Accumulation of an endog-
human renal disease. enous inhibitor of nitric oxide synthesis in chronic renal failure.
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